Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
AstraZeneca Unveils The Discovery Centre (DISC) in Cambridge
AstraZeneca will today, in the presence of His Royal Highness The Prince of Wales, formally […]
Two Billion Doses of AstraZeneca’s COVID-19 Vaccine Supplied to Countries Across the World Less Than 12 Months After First Approval
AstraZeneca and its partners have released for supply two billion doses of their COVID-19 vaccine […]
SAGA Diagnostics Enters into Development Agreement with AstraZeneca
SAGA Diagnostics AB, a cancer liquid biopsy and genomic testing company focused on precision oncology […]
AZD7442 Reduced Risk of Developing Severe COVID-19 or Death in TACKLE Phase III Outpatient Treatment Trial
Positive high-level results from the TACKLE Phase III COVID-19 treatment trial showed AstraZeneca‘s AZD7442, a […]
Enhertu Granted Breakthrough Therapy Designation in US for Patients with HER2-positive Metastatic Breast Cancer Treated with One or More Prior Anti-HER2-based Regimens
The Food and Drug Administration (FDA) has granted Enhertu (trastuzumab deruxtecan), Breakthrough Therapy Designation (BTD) in the […]
VaxEquity Announces Strategic Collaboration with AstraZeneca to Commercialise Self-Amplifying RNA Platform
VaxEquity, developing transformative RNA vaccines and therapeutics based on its next generation self-amplifying RNA (saRNA) […]
AstraZeneca to Invest $360m in Advanced Manufacturing Facility in Ireland
AstraZeneca is planning on establishing a next-generation active pharmaceutical ingredient (API) manufacturing facility for small […]
Imfinzi Plus Chemotherapy Tripled Patient Survival at Three Years in the CASPIAN Phase III Trial in Extensive-stage Small Cell Lung Cancer
Updated results from the CASPIAN Phase III trial showed AstraZeneca’s Imfinzi (durvalumab) in combination with a choice […]
Thermo Fisher Scientific and AstraZeneca to Co-Develop NGS-based Companion Diagnostics
Thermo Fisher Scientific‘s clinical sequencing business and AstraZeneca today announced they will co-develop next-generation sequencing […]
Forxiga Approved in the EU for the Treatment of Chronic Kidney Disease in Patients With and Without Type-2 Diabetes
AstraZeneca’s Forxiga (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved in the European Union (EU) […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more